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Abstract: Inflammatory bowel diseases are chronic gastrointestinal pathologies causing great 
discomfort in both children and adults. The pathogenesis of inflammatory bowel diseases is not 
yet fully understood and their diagnosis and treatment are often challenging. Nanoparticle-based 
strategies have been tested in local drug delivery to the inflamed colon. Here, we have investi-
gated the use of the novel avidin-nucleic acid nanoassembly (ANANAS) platform as a potential 
diagnostic carrier in an experimental model of inflammatory bowel diseases. Fluorescent- 
labeled ANANAS nanoparticles were administered to mice with chemically induced chronic 
inflammation of the large intestine. Localization of mucosal nanoparticles was assessed in 
vivo by dual-band confocal laser endomicroscopy. This technique enables characterization of 
the mucosal microvasculature and crypt architecture at subcellular resolution. Intravascular 
nanoparticle distribution was observed in the inflamed mucosa but not in healthy controls, 
demonstrating the utility of the combination of ANANAS and confocal laser endomicroscopy 
for highlighting intestinal inflammatory conditions. The specific localization of ANANAS in 
inflamed tissues supports the potential of this platform as a targeted carrier for bioactive moieties 
in the treatment of inflammatory bowel disease. 
Keywords: confocal laser endomicroscopy, inflammatory bowel disease, diagnostics, dextran 
sodium sulfate, avidin-nucleic acid nanoassembly, fluorescent nanoparticles, ulcerative colitis
Introduction
Crohn’s disease  and ulcerative colitis are chronic inflammatory bowel diseases (IBD) 
with a severe impact on social life, reducing quality of life and the ability to work as 
a consequence of increasing disability. IBD are chronic diseases with symptoms of 
bloody diarrhea and abdominal cramp. They generally begin in young adulthood and 
last throughout life, with nearly 80% of patients with Crohn’s disease and 30% of those 
with ulcerative colitis requiring intestinal surgery. There is a strong need for novel 
strategies to improve the diagnosis and treatment of IBD. Indeed, the pathogenesis 
of these diseases is not yet fully understood1–3 and their diagnosis and treatment are 
often challenging. Standard treatments to induce disease remission include amin-
osalicylates, corticosteroids, and immunosuppressive agents such as thiopurines and 
anti-tumor necrosis factor-α. Immunomodulator and combination therapies constitute 
a significant advance in the management of IBD.4–7 However, the onset of action is 
delayed with some of these drugs, and/or important adverse systemic effects often 
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occur, including anaphylactic/anaphylactoid8,9 and lupus 
symptoms, and bacterial, viral, or fungal infections.10–12 
A possible way to reduce side effects without losing 
efficacy is to use targeting strategies to increase drug tro-
pism to the inflamed sites. This strategy could improve drug 
therapeutic indices and the development of more effective 
treatment schedules. In recent years, several nanoparticle 
and colloidal systems have shown enhanced accumulation 
at inflamed sites due to hypervascularization13 or in tumors 
because of ineffective lymphatic drainage.14 These systems 
have the advantage of being able to carry a high drug payload/
circulating unit, and in principle they could address the need 
for targeted delivery of active agents to IBD sites. Further, 
the mucosal epithelium is characterized by leaky structure in 
IBD15 and this particular feature may offer an opportunity for 
selective drug targeting through use of colloidal carriers.
In this work, we evaluated the behavior of a recently 
described nanoparticle platform, ie, an avidin-nucleic acid 
nanoassembly (ANANAS), when administered parenterally 
in a mouse model of IBD. ANANAS are fully biodegradable 
and biocompatible particles consisting of a compositionally 
defined poly-avidin core capable of accommodating more 
than 1,000 biotin-linked moieties of different kinds with 
unique stoichiometric and compositional control through 
a one-pot synthetic process.16 Recently, the potential of the 
ANANAS formulation as a theranostic carrier for intrave-
nous administration was demonstrated. The nanoparticles 
are capable of circulating for at least 2 hours before being 
eliminated within the next 2 days through classic scavenging 
systems with no apparent toxicity and low immunogenicity.17 
These findings paved the way for further exploitation of 
this nanoparticle tool for in vivo diagnostics and delivery 
applications.18 The ANANAS platform is especially inter-
esting because it also meets the current need for convenient 
and reproducible preparation methods for multifunctional 
nanocarriers.19 Multifunctionality in nanoparticles, while 
offering great potential for targeted treatments, significantly 
increases the complexity of preparation methods. As a con-
sequence, the availability of standardized and reproducible 
synthetic procedures to control the multifunctional carrier 
composition is mandatory for translating research findings 
into clinical practice.
Here, in a further attempt to evaluate the clinical poten-
tial of this nanoparticle technology in nanomedicine, we 
generated a near red-emitting fluorophore-labeled ANANAS 
formulation (ANANAS-red681), and performed a preliminary 
investigation of its distribution after intravenous adminis-
tration in the colonic mucosa of an experimental model of 
IBD. Confocal laser endomicroscopy (CLE) is a noninvasive 
fluorescence-based diagnostic tool for assessment of in vivo 
histology of the mucosa at subcellular resolution during ongo-
ing endoscopy.20 Probe-based CLE is a system designed for 
the in vivo characterization of the gastrointestinal mucosa 
and is currently used in the preclinical21,22 and clinical 
diagnostics23–25 of IBD. Intravenous administration of the 
green fluorescent dye fluorescein as a contrast agent allows 
visualization of the morphology of mucosal crypts and micro-
vasculature. Dual-band CLE is a research-dedicated system 
that generates two-color laser excitation (488 nm/660 nm) 
and permits real-time dual-band fluorescence detection 
(500–630 nm/680–800 nm). This tool allows detection of 
two different fluorophore-related probes within the mucosal 
environment of interest and thus simultaneous visualization 
of different structures and/or targets. 
In this pilot study, ANANAS-red681 was administered 
intravenously together with low molecular weight fluorescein 
solution in order to determine the distribution of nanopar-
ticles within the colonic mucosa, the architecture of which 
is highlighted by fluorescein. The red681 fluorophore was 
used to enable nanoparticle visualization in the colonic 
microvasculature by CLE. In principle, the fluorophore 
can be substituted with bioactive compounds to develop a 
therapeutic application. 
Materials and methods
Animal study approval
Procedures involving animals and their care were conducted 
in compliance with Research Project 27/2013 (protocol num-
ber 28893 May 13, 2013). The project proposal was approved 
by the Institutional Animal Care and Use Committee of the 
University of Padova according to Italian and European 
Commission regulations on Laboratory Animal Welfare 
and Protection (legislative decree number 116/92), which 
acknowledges the European Directive 86/609 EU.
Induction of dextran sodium sulfate 
colitis
Chronic colitis was induced in Balb/c mice26,27 (female, aged 
8–10 weeks) with dextran sodium sulfate (DSS, molecular 
mass 40,000 Da), according to a protocol specifically opti-
mized and described in detail in the Supplementary material. 
During treatment, animal body weight, rectal bleeding, stool 
consistency, and the presence of blood in stools were assessed 
daily. Assessment of chronic inflammation was confirmed by 
histological analysis.28 Mice given untreated drinking water 
were used as controls.
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Synthesis of biotin derivatives used 
for nanoparticle assembly 
The synthetic steps are summarized in Figure 1. Compound 
1 and biotin-C
6
-NH
2
 (compound 2) were obtained as 
described elsewhere.29 Compound 3 was obtained by react-
ing compound 2 with fluorescent red681 succinimidyl ester 
(red681-NHS, Sigma Aldrich, St Louis, MO, USA, catalog 
number 53433) in dry dimethyl sulfoxide at a molar ratio of 
1:1.1 in the presence of triethylamine.
In more detail, 45.9 µL of a biotin-C
6
-NH
2
·HCl solution 
in dry dimethyl sulfoxide (9.3 mg/mL) was added to 49 
µL of red681-NHS in dry dimethyl sulfoxide  (20 mg/mL), 
followed twice by 7.7 µL (2×7.7) of triethylamine 1:50 
in dry dimethyl sulfoxide. The product (biotin-red681) 
was characterized for its ability to bind avidin through 
gel permeation chromatography and for its fluorescence 
intensity before and after avidin binding (Supplementary 
material).
Preparation of ANANAS-red681
The term ANANAS refers to a series of poly-avidin nano-
particle formulations originating from the high affinity 
interaction of avidin with nucleic acids.30 These buffer-
soluble nanoparticles are formed by a spontaneous double 
self-assembly in which a nucleic acid molecule acts as a 
central element around which several avidins (one for each 14 
base pairs) nucleate, leading to toroidal assemblies (diameter 
approximately 120 nm). In a second self-assembly process, a 
defined amount of biotinylated poly(ethylene glycol) (PEG) 
is added to permit buffer solubility and increase stability.29 
Finally, the ANANAS assemblies are polymerized forms 
of avidin. In this study, red681-labeled ANANAS nanopar-
ticles were synthesized in collaboration with ANANAS 
Nanotech (Padova, Italy) according to a procedure described 
elsewhere.17 In detail, a highly PEGylated ANANAS nano-
particle formulation was prepared and stabilized by mixing 
plasmid DNA and a complex of avidin and compound 1 at 
1:0.25 molar ratio.17,29 After purification and ultraviolet-
visible characterization of the nanoassembly, biotin-C
6
-red681 
(compound 3) was added to at 1:3 avidin:biotin molar ratio. 
Finally, the mixture was purified from low molecular weight 
derivatives by gel permeation chromatography using a Sep-
harose 6-FF column on a fast protein liquid chromatography 
system (AKTA purifier, GE Healthcare, Little Chalfont, UK) 
with 10 mM phosphate, 150 mM NaCl pH 7.4 (phosphate-
buffered saline) as the eluent. Four hundred and seventy five 
fluorophores/nanoparticles were found to be stably attached, 
as determined from the assembly ultraviolet-visible spec-
trum on the basis of the 280 nm (avidin, DNA, and red681) 
and 681 nm (red681) absorption values. The assembly size 
Biotin-CONH(CH2)6-NH
HN
NH
O
O
O
O
O
O
O
O
ON
N
N
O+
t-Bu
t-Bu
O+ SO3
–
O
PEG5kDa-OCH3
PEG5kDa-OCH3
Biotin-CONH(CH2)6-NH2
Biotin-CONH(CH2)6-NH
(2)
(2)/TEA
(1)
(3)
DMSO, RT
Fluorescent red681, NHS
Sigma-Aldrich, cat 53433
Biotin-C6-Red681
SO3Na
SO3Na
SO3
–
Biotin-C6-NH2Biotin-(mPEG5kDa)2
Figure 1 Synthesis of biotin derivatives used in assembly of ANANAS-red681.
Abbreviations: ANANAS, avidin-nucleic acid nanoassembly; DMSO, dimethyl sulfoxide; TEA, triethylamine; RT, room temperature; NHS, N-hydroxysuccinimide; 
PEG: poly(ethylene glycol).
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was approximately 120 nm as measured by dynamic light 
scattering (Supplementary material).
Confocal laser endomicroscopy
We used the Cellvizio Dual Band system integrated with Pro-
flex Ultra Mini O/Z probes (Mauna Kea Technologies, Paris, 
France) and a flexible endoscope (MAS-GM, Olympus, Italia 
S.r.l., Milano, Italy). Post-processing imaging analysis was 
performed using IC-viewer software. CLE was carried out 
on anesthetized healthy and diseased mice after endoscopic 
confirmation of mucosal damage. Fluorescein in phosphate-
buffered saline solution, in the presence or absence of ANAN-
AS-red681 (100 µg/mouse), was administered intravenously 
(100 µL) in healthy and DSS-treated animals (three animals 
per condition) and CLE images were acquired 15–30 minutes 
after injection. Longer observation times could not be used 
due to the rapid fluorescein clearance.
Results and discussion 
Optimization of fluorescein dosage for 
dual-band CLE investigation
Preliminary experiments were carried out to optimize 
experimental conditions to provide the most valuable 
biological information using the dual-band probe. When 
using dual-band fluorescence imaging, if the signal gener-
ated by one fluorophore is too high, signal cross-over into 
the second channel may occur, resulting in false-positive 
readings. In our experiments, the concentration of red681 
dye in the injected nanoparticle formulation was several 
orders of magnitude lower (0.00167% w/v) than that of the 
fluorescein dye normally used for single-band CLE-assisted 
visualization of the microvasculature (between 10% and 
0.5% w/v).31 Since this was the first application of dual-band 
CLE for preclinical research in IBD, we tested a range of 
fluorescein concentrations to eliminate the risk of a false-
positive signal from fluorescein interfering with specific 
red681-related signals. 
In this preliminary investigation, healthy and inflamed 
animals were injected with different fluorescein solutions 
(0.1%, 1.0%, and 10% w/v in phosphate-buffered saline) at 
100 µL/dose to identify the fluorophore concentration allow-
ing the morphology of the vasculature (in the green channel) 
to be reliably distinguished without generating cross-over of 
fluorescent emission in the red channel. Only the intermediate 
fluorescein concentration tested was found to be suitable for 
our purposes (Figure 2). 
Administration of the 10% dye solution generated a 
strong and diffuse signal in the green channel, together with 
a significant bleed-through of fluorescent emission in the red 
channel. The diffuse signal, likely due to diffusion of the 
dye from the vessels to the surrounding stroma, impaired 
visualization of crypt and microvasculature architecture. In 
addition, the strong spectral cross-over effect prevented reli-
able identification of a positive signal due to the red-emitting 
dye in the red channel. Using 0.1% fluorescein, no bleed-
through was observed in either healthy or inflamed mucosae, 
but the microvasculature pattern was poorly defined. Finally, 
1% fluorescein was found to be suitable for our purposes, 
because it allowed the crypt and microvascular architecture 
to be visualized in a manner similar to that possible with 
use of 10% fluorescein in human clinical practice,23 with 
negligible spectral cross-over in either healthy or chronically 
inflamed mucosae.
ANANAS-red681 reaches mucosal 
microvasculature in inflamed but 
not healthy bowel
ANANAS-red681 were coinjected with 1.0% fluorescein. 
Selective detection of nanoparticles was observed exclusively 
in the inflamed tissue (Figure 3). The red signal appears in the 
inflamed vessels (highlighted by the green fluorescein) only, 
and is clearly related to the presence of ANANAS-red681, as 
confirmed by the merged images. The speckled red signal is 
likely due to the low fluorophore concentration (0.00167% 
red681 versus 1% fluorescein w/v), the discrete concentra-
tion of nanoparticles, and the lower relative brightness of 
red681 as compared with fluorescein (not shown). The results 
therefore confirm that, like other colloidal drug carriers, 
ANANAS nanoparticles are capable of selectively reaching 
inflamed tissues. Of note, when CLE probing was performed 
on healthy regions of the patchily inflamed colon, no red681 
signal was observed (not shown). This indicates that the 
system can discriminate between healthy and inflamed areas 
in the same organ.
Conclusion
In these preliminary studies, dual-band CLE was used for 
the first time to characterize the architecture of the micro-
vasculature and visualize fluorescent-labeled nanoparticles 
simultaneously in an in vivo model. A distinctive pattern of 
distribution of intravascular nanoparticles was observed in 
chronic inflamed mucosa compared with healthy controls. The 
results confirm that ANANAS  nanoparticle-based delivery 
strategies have the ability to reach the microvasculature of 
inflamed bowel mucosa together with their cargo. This result 
further supports the potential of this novel soft biodegradable 
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Figure 2 Confocal laser endomicroscopic images of healthy and chronically inflamed mucosa in the green and red channels.
Notes: The images were obtained after intravenous administration of fluorescein at different concentrations (10%, 1.0%, and 0.1% w/v). Each image represents one example 
of three per group of animals per condition. The images obtained in the green channel (A1–A3 and B1–B3) show the hexagonal honeycomb appearance of the mucosa. 
Nonideal fluorescein concentrations yield either overexposed images (10%, A1 and B1) or loss of details (0.1%, A3 and B3). Normal mucosa shows a network of capillaries 
surrounding the crypt openings with a honeycomb appearance. In inflamed mucosa, the crypt lumen is large and variably shaped, with fluorescein leakage into the crypt 
openings (arrows in B2). In the red channel (A4–A6 and B4–B6), any visible structure (A4 and B4) is due to fluorescein-related signal cross-over.
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nanoparticle platform as a tool for targeted delivery of 
diagnostic agents. It should be noted that due to the high 
compositional versatility of the platform and its ease of formu-
lation and tuning, part or all of the diagnostic elements could 
be substituted with therapeutic agents, making the nanosys-
tem a potential carrier for targeted drug delivery to inflamed 
mucosa. The results are encouraging for future development 
of the platform, although additional studies are necessary 
before translation into clinical practice. On the diagnostic side, 
future experiments aimed at determining the duration of dis-
tribution and optimization of nanoparticle concentration are 
warranted. In the context of targeted drug delivery, research 
should focus on the development of linker technologies to 
enable efficient local release of the biotin-linked bioactive 
agent as soon as the nanoparticles reach their target.
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Supplementary material
Figure S1 shows the gel permeation chromatography analy-
sis of biotin-C
6
-red681 (compound 3) before and after addi-
tion of avidin. Figure S2 shows the fluorescence intensity 
calibration curves of the same compound in phosphate-
buffered saline, alone and in the presence of avidin. Figure 
S3 shows the results of dynamic light scattering analysis 
of the avidin-nucleic acid nanoassembly (ANANAS)-red681 
nanoparticles. Figure S4 shows histological images of 
colonic mucosa in dextran sodium sulfate (DSS)-treated 
and healthy mice. 
Characterization of biotin-C6-red
681
For analysis, a small aliquot of the coupling reaction solu-
tion (0.5 µL) was diluted to 218 µL with phosphate-buffered 
saline alone or phosphate-buffered saline containing avidin 
1 mg/mL (Belovo Chemicals, Bastogne, Belgium), and 
analyzed by fast protein liquid chromatography (Superdex 
peptide column with phosphate-buffered saline as the elu-
ent, 0.5 mL/min, ultraviolet absorption 681 nm). Figure S1 
shows the overlapped chromatograms of the starting red681-
NHS, the reaction product as before and after the addition of 
avidin, with peak assignments. The hydrolyzed red681-NHS 
(Red681-COOH) and its biotin derivative were tested for fluo-
rescence intensity. The biotin derivative was also tested upon 
addition of avidin. Fluorescence intensity calibration curves 
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Figure S1 Chromatographic analysis of red681 derivatives. (A) Starting NHS reagent, 
(B) biotin-C6-red
681 derivative (compound 3), and (C) compound 3 in the presence 
of avidin.
Notes: Analyses were carried out using fast protein liquid chromatography 
apparatus (Akta Purifier, GE Healthcare, Little Chalfont, UK) equipped with a 
superdex peptide column and eluted with 10 mM phosphate, 150 mM Nacl, ph 
7.4 (phosphate-buffered saline) at 0.5 mL/min. Chromatograms were registered at 
681 nm.
Abbreviations: ANANAS, avidin-nucleic acid nanoassembly; NHS, 
N-hydroxy succinimide.
were generated on serially diluted phosphate-buffered saline 
solutions, starting from 1 µM red681, with λ
exc
 681 nm and 
λ
em
 708 nm. The slope of the fluorescence intensity versus 
concentration curve was used to calculate the relative fluo-
rescence intensity with respect to the starting red681-COOH. 
The fluorescence intensity of avidin-linked biotin-C
6
-red681 
was 43% that of the same reagent when analyzed free in solu-
tion. The same result was obtained using ANANAS instead 
of avidin (not shown).
Size distribution of ANANAS 
nanoformulation
Dynamic light scattering measurements were per-
formed using a Malvern Zetasizer Nano ZS (Malvern 
Instruments Ltd, Malvern, UK) and the results are shown 
in Figure S3.
Induction of Dss chronic colitis
Chronic colitis was induced in Balb/c female mice1,2 (aged 
8–10 weeks) by using multiple cycles of dextran sodium sul-
fate (DSS, 40 kDa, Sigma-Aldrich, St Louis, MO, USA). We 
performed preliminary optimization experiments to identify 
the optimal DSS dose and administration schedule yielding 
chronic inflammation. During treatment, animal body weight, 
rectal bleeding, stool consistency, and the presence of blood 
in stools were assessed daily. Assessment of chronic inflam-
mation was confirmed by histological analysis. The final 
induction protocol identified is reported below: initially, we 
administered two cycles comprising 7 days of 3% DSS in 
drinking water and 3 days of untreated drinking water. Next, 
5% DSS was administered for 3–4 days until a 10% weight 
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Figure S2 Fluorescence intensity versus concentration of red681-COOH (•) and 
biotin-C6-red
681 as before (), and in the presence of avidin ().
Abbreviation: RIU, relative intensity units.
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Figure S3 (A) Intensity and (B) volume weighted size distribution of ANANAS assembly prepared for this work, as determined by dynamic light scattering.
Abbreviation: ANANAS, avidin-nucleic acid nanoassembly.
Figure S4 Histology images of dextran sodium sulfate-treated (A, B) and healthy (C) mouse colonic mucosa.
Notes: Colonic segments, fixed in 4% formaldehyde, were stained with hematoxylin and eosin and reviewed by a pathologist in a blinded fashion. Original magnification for 
histology, 40×. 
loss was achieved, then substituted with untreated drinking 
water for 3 days or until full body weight recovery. The 
5% DSS/untreated drinking water cycle was repeated four 
times. Inflammatory changes3 (crypt architectural disarray, 
transmural inflammation with lymphoid follicles) were con-
firmed histologically in colonic sections from DSS-treated 
mice compared with control mice (Figure S4).
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